海南海藥(000566.SZ):與上海藥物所簽署神經精神疾病藥物研究聯合實驗室合作協議
格隆匯 11 月 17日丨海南海藥(000566.SZ)公佈,公司近期與中國科學院上海藥物研究所(“上海藥物所”)簽署《神經精神疾病藥物研究聯合實驗室合作協議》。基於雙方前期在神經精神創新藥物研發方向的良好合作基礎,本着“平等互利、合作共贏、共促發展”的原則,經友好協商,決定共同建設“神經精神疾病藥物聯合實驗室”。協議期間,由海南海藥設立專項資金,提供運營、研發經費。因該聯合實驗室不是獨立的法人實體,相關專項資金將由公司向上海藥物所支付。由上海藥物所根據“專款專用”的原則進行有序的資金規劃和使用,公司有權定期審查經費的使用情況。
通過聯合實驗室,雙方共同推動國內領先、國際先進的神經精神疾病研究中心建設,促進我國神經精神藥物創新,同時為海南海藥的神經精神藥物創新研發培養人才及培育更豐富的項目資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.